Dr Richard Mason is Apollo Therapeutics’ chief executive officer. Richard has over 20 years’ experience in the biopharmaceutical industry, including leading Johnson & Johnson Innovation in Europe. Before this, he was CEO of novel anticoagulant antibody company XO1 until the company was acquired by Janssen in March 2015. Previously, Richard was the executive leadership team member responsible for strategy and business development at listed companies BTG Plc and Cambridge Antibody Technology Plc where he led numerous M&A and partnering transactions. Richard received degrees in medicine from St Bartholomew’s Hospital Medical College and immunology from University College London and trained in internal medicine in London. During 2020, he served on active duty with the British Army as part of the UK government’s pandemic response, including as a member of the UK Vaccines Task Force.